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Abstract
We probed the ability of reverse lysate
array technology to help explain potential dif-
ferences in the responses of cancer cells to 
various small-molecule kinase inhibitors. To
understand the antitumor potential of signal
transduction inhibitors and their effects on sig-
naling pathways downstream of Src, we used
reverse lysate array technology to study
SIG11293, a selective inhibitor of Src and Lck
kinases, and AEE788, a selective inhibitor of
Kdr (VEGFR1) and epidermal growth factor
receptor/ErbB-2 that also has affinity for Src,
c-abl, c-fms, and Flt-1. We observed the effects
of drug dose on cell killing and expression and
phosphorylation of various signal transduction
proteins in MDA435 and MDA231 human
breast cancer cells and U251HF glioblastoma
cells. After 24 h, SIG11293 induced the least
amount of cell killing in MDA435 cells;
decreased Stat3(pY705) and Src(pY529) in all
cell lines; decreased Src(pY418) and total Src in
MDA231 and MDA435 cells, but not U251
cells; and in U251 cells, uniquely increased
activated caspase 3, Src(pY418), panSrc, and
p70S6K. AEE788 decreased Src(pY529) and
Stat3(pY705) in U251HF and MDA435 cells.
In regard to Src phosphorylation, both drugs
decreased the negative regulatory site, Src
(pY529), more than the positive regulatory site,
Src(pY418), relative to total Src. These observa-
tions suggest that the two drugs have complex
and different effects on Src signaling pathways.
Although this general conclusion could be pre-
dicted, we believe that these studies exemplify
the ability and robustness of reverse lysate
arrays to measure signaling pathway modula-
tion in tumor cells. Our hope is that these tech-
niques will help to develop more robust
preclinical and, eventually, clinical treatment
paradigms.
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Introduction
The therapeutic potential of small-molecule
drug inhibitors of specific signaling pathways
largely is assessed by their affinity to a target or
group of targets. A drug is deemed to be spe-
cific with respect to target and mode of action in
vitro if there is at least one order of magnitude
difference between its affinity with or response
from the main target compared with its affinity
to or response from other possible targets.
Unfortunately, it is often difficult to assess a
drug’s function within a particular tumor
because of the potential for nonlinear interac-
tions among signaling molecules, the unknown
time- and dose-dependent changes in signal
transduction caused by the drug, the inherent
pharmacodynamic and pharmacokinetic het-
erogeneity in response to the drug, and the
inherent heterogeneity of tumor cell functions.
Although the recently developed small-
molecule inhibitors of receptor and non-
receptor protein tyrosine kinases (PTKs) are
attractive conceptually, they are far from 
specific or selective in their abilities to inhibit
the kinases in a constant manner and with 
a constant outcome. The relative differences
between the affinities of the inhibitors for their
target kinases in vitro often do not reflect their
inhibitory values for enzymes in cells. Indeed,
small-molecule inhibitors cannot be easily
tested against all potentially competing
kinases in cells, let alone in situ in the tumor of
interest. This problem is more apparent in the
case of receptor and nonreceptor PTK
inhibitors, as signaling pathways within cells
of different tumors interact variably when
confronted with the many intra- and extracel-
lular influences. Even in cultured cells, the
response to a PTK inhibitor can produce dis-
parate effects depending on the dose of
inhibitor, length of exposure to the drug, and
inherent genetic instability of tumor cells.
These aforementioned difficulties are likely
to account for some of the variable responses
of patients to targeted therapies and strongly
suggest that profiling the targeted kinases and
their associated pathways in tumor cells is
crucial to a rational understanding of tumor
response to inhibitors. Thus, in an effort to
better define the similarities and differences
among cancer cell lines and between small-
molecule kinase inhibitors, we initiated the
reverse lysate array studies of kinase inhibitors
presented in this article.
The inhibitors used in this study were
selected for their ability to inhibit Src-kinase
activity. SIG11293, a thienopyrimidine, was
chosen because it is a primary Src-kinase
inhibitor, although it does have a similar half-
maximal inhibitory concentration for Lck 
(1). AEE788, a 7H-pyrrolo-[2,3-D]-pyrimidine
inhibitor, was chosen because it primarily
inhibits Kdr (VEGFR1) and epidermal growth
factor receptor (EGFR)/ErbB-2 kinase activity
and has lower half-maximal inhibitory concen-
tration values for Src, c-abl, c-fms, and Flt-1 (2).
The use of reverse lysate arrays to probe
changes in protein and phosphoprotein
expression was predicated on its potential to
study, in a semiquantitative manner, nonde-
natured cellular proteins from cultured tumor
cells. Although reverse lysate arrays have
been used to analyze cancer cells from tissue,
cultured cells, cells treated with drugs, and
T-lymphocytes (3), use of reverse lysate arrays
in the field of cancer research remains rela-
tively young. An encouraging study by Her-
rmann et al. (4) used this technology to assess
the mitochondrial proteome in prostate cancer.
In that study, reverse lysate arrays, Western
blots, and immunohistochemistry were used
to examine mitochondrial cytochrome c oxi-
dase levels in four prostate carcinoma and six
other cancer biopsy samples in an effort to
better understand the malignant phenotype.
In another study, Chan et al. (5) used reverse-
phase lysate microarrays to probe specific 
04_Levin.qxd  11/21/06  3:11 PM  Page 34
Volume 2, 2006 ________________________________________________________________ Clinical Proteomics
Lysate Array Analyses of Signal Transduction Inhibitors ___________________________________________ 35
protein phosphorylation in 62 signaling sites
in stimulated Jurkat T cells. Last, Utz wrote a
scholarly review of protein arrays and their
application for the study of blood cells and
their secreted products; he expects array tech-
nology will markedly influence immunology
research in the fields of autoimmunity and
inflammation (3).
We used the quantitative reverse lysate
array technology to evaluate the ability of
SIG11293 and AEE788 to effect cell killing and
changes in representative proteins and phos-
phoproteins in three cancer cell lines. The
experiments presented provide a strategy for
profiling kinases and inhibitors using discrete
tumor cell lines.
Materials and Methods
Cell Cultures
We used two human breast carcinoma
lines, MDA435 and MDA231 (gift from 
Francisco Esteva, The University of Texas 
M.D. Anderson Cancer Center), that differ in
their degree of malignancy (6), ability to
metastasize in nude mice (7), and sensitivity
to Src inhibitors (8). We also used the U251HF
human glioblastoma multiforme cell line 
(a gift from Juan Fueyo, The University of
Texas M.D. Anderson Cancer Center), which
responds to Src inhibitors through an apop-
totic pathway (8). Our choice of cell lines was
based partly on their disparate levels of
dependence on Src kinase pathways and sen-
sitivities to inhibitors of Src and other signal
transduction molecules.
U251HF cells were maintained in Dul-
becco’s modified essential/F12 medium sup-
plemented with 5% fetal bovine serum (FBS).
MDA435 and MDA231 cells were maintained
in Leibovitz’s L-15 medium supplemented
with 5% FBS. 
K562 chronic myelogenous leukemia cells (9)
(a gift of Nicholas Donato, The University of
Texas M.D. Anderson Cancer Center) served as
negative control cells for all Src antibodies and
were grown in RPMI 1640 medium. SW480
colon cancer cells (a gift from Gary Gallick, The
University of Texas M.D. Anderson Cancer
Center) transfected with an expression plasmid
(c-srcY527F) expressing constitutively active Src
(10) served as the positive control cell for all Src
antibodies and were maintained in Leibovitz’s
L-15 medium supplemented with 5% FBS.
Drugs
SIG11293, a thienopyrimidine with a molec-
ular weight of 434, was a gift from Raymond
Budde (Signase, Houston, TX). AEE788, a 
7H-pyrrolo-[2,3-D]-pyrimidine with a molecu-
lar weight of 441, was a gift from Novartis
Pharmaceutical Research (Princeton, NJ). Both
drugs were dissolved in dimethylsulfoxide
and stored as 5 mg/mL stock solutions at
room temperature.
Lysis Buffer
The lysis buffer stock solution was prepared
in 50-mL volumes using 1 mL of 1 M Tris-
HCl (pH 7.6; final concentration of 20 mM), 
1.5 mL of 5 M NaCl (final concentration of 
150 mM), 0.5 mL of 0.5 M EDTA (pH 8.0;
final concentration of 5 mM), and 46.75 mL
of double-distilled water. The solution was fil-
tered, autoclaved, and stored at 4°C. Immedi-
ately before lysing the cells, we added to the
stock solution five protease inhibitor cocktail
tablets (EDTA-free complete mini-tablets;
Roche Applied Science, Indianapolis, IN), 10.5
mg of 5 mM sodium fluoride, 9.2 mg of 1 mM
sodium orthovanadate, 115 mg of 5 mM
sodium pyrophosphate, and 250 µL of Igepal
CA-630 to make a 0.5% solution.
Primary Antibodies
Commercial rabbit polyclonal antibodies
were used to detect Tyr418-phosphorylated
Src (Src[pY418]; 1:250), Src(pY529) (1:250),
panSrc (1:250), and Stat3(pY705) (1:250; all
from Biosource International, Camarillo, CA);
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and p38MAPK(pY180/pY182) (1:250) and
p70S60K(pT389) (1:250; both from Cell Signal-
ing Technology, Beverly, MA). Monoclonal
rabbit antibody was used to detect active 
caspase 3 (1:100; BD Biosciences, Palo Alto,
CA). Polyclonal rabbit antibody against β-
actin (1:1000; Santa Cruz Biotechnology, Santa
Cruz, CA) was used as a positive control. 
Primary antibody was omitted as a negative
control. We confirmed that all primary anti-
bodies had only one dominant band, except
for activated caspase-3, which had two bands
as expected.
Cell Counts
U251HF, MDA231, and MDA435 cells 
(1 × 104 each) were seeded on 24-well plates
with Dulbecco’s modified essential/F12
medium or Leibovitz’s medium supplemented
with 5% FBS and incubated for 24 h. The 
following day, the medium was replaced with
FBS-free medium containing SIG11293 and
AEE788 at various concentrations (0.1, 1, and
10 µM).
For cell counting, the cells were incubated
with the drugs for 24 h and then trypsinized,
suspended in phosphate-buffered saline, and
counted using a Vi-Cell cell viability analyzer
(Beckman Coulter, Fullerton, CA). The data
were analyzed by averaging triplicate values
for each treatment and calculating the ratios
of treated to untreated cell numbers for all
doses and cell lines tested using the equation,
cell kill = (1 – treated cell number/control cell
number) × 100. 
Preparation of Samples 
for Microarray Analysis
To prepare cell lysates for microarray exper-
iments, cells were plated in flasks on sequen-
tial days. Concentrations were maintained at
106 cells/mL or less to avoid natural induction
of apoptosis by cell confluence. Cells were
harvested using 0.25% trypsin and counted,
and 5 × 106 cells were transferred into a 6-well
plate (35-mm diameter, 5-mL volume) and
incubated for 24 h at 37°C in 5% CO2.
SIG11293 and AEE788 were added to the
medium at 0.1, 1.0, and 10 µM, and the cells
were again incubated for 24 h at 37°C in 5%
CO2. The cells were then harvested by scrap-
ing and transferred with medium into 15-mL
tubes (BD Falcon, Franklin Lakes, NJ) on ice
and spun for 5 min at 4°C and 16,100g. The
medium was removed and discarded, and the
remaining cells were lysed with 0.5-mL lysis
buffer on ice and mixed by pipetting. After 30
min on ice, the tubes were spun for 20 min at
4°C and 16,100g. Fifty microliters of super-
natant from each tube were transferred to a
96-well plate (Eppendorf, Westbury, NY), and
the plates were stored at –80°C until use.
Reverse-Phase Protein Lysate 
Microarray Printing
Slides of six dilutions of each of the sam-
ples in triplicate were made by a liquid-
handling RSP robot (TECAN US, Research
Triangle Park, NC). The dilutions were then
spotted onto nitrocellulose-coated FAST slides
(Scheicher and Schuell, Keene, NH) with a
500-µm center-to-center interspot distance
using a G3 spotter (Genomics Solutions, Ann
Arbor, MI). Triplicate spots of each dilution
point were produced, with six transfers for
each dilution. 
Detection and Imaging
A heavily modified catalyzed signal amplifi-
cation kit (cat. no. K1500; DakoCytomation,
Carpinteria, CA) was used to detect target pro-
teins. Briefly, the slides were blocked with 
Re-Blot Plus mild solution (cat. no. 2502;
Chemicon, Temecula, CA) and then blocked
overnight with I-block (cat. no. Tropix AI300;
Applied Biosystems, Foster City, CA). Blocking
was continued the following day with fresh 3%
hydrogen peroxide, avidin/biotin, and casein.
Primary antibodies were diluted in antibody
dilution buffer and incubated with the slides at
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25°C for 1 h in a humidified chamber. Sec-
ondary biotinylated antirabbit (BA-1000) or
antimouse (BA-9200) antibodies (Vector Labo-
ratories, Burlingame, CA) were diluted 1:10,000
and incubated with the slides at 25°C for 1 h.
The slides were then incubated with strepta-
vidin/biotin, amplification reagent, and strep-
tavidin/peroxidase from the kit followed by
development with DAB+ (Dako). After each
step, the slides were washed with 0.1% Tris-
buffered saline containing Tween (pH 7.4) to
remove the previous reagents. The slides were
scanned in color at 1200 dots per inch; the
resulting image was converted to a 16-bit
grayscale image and inverted to allow quantifi-
cation by ArrayVision software (Imaging
Research, St. Catharines, Ontario, Canada).
Analysis of Relative Amounts 
of Primary Antibodies
Lysate arrays are more susceptible than
microarrays to artifacts, such as saturation,
membrane irregularities, or improper spot seg-
mentation. To estimate a single value for each
sample (defined as lysate expression), we used
an exponential least-squares fit (Y = ABX) to fit
the 18 spots (sixfold dilutions with three repli-
cates for each dilution). In most cases, our data
easily fit a simple exponential least-squares
plot of the intensity vs 1-dilution, in which the
dilutions ranged from 1:1 to 1:32 (1 to 0.03125).
Variance was typically 10% or less. Figure 1
shows a representative plot of the triplicate
data points at each of the six dilutions for a 10
µM dose of SIG11293 in MDA231 cells probed
with anti-Src(pY418) antibody.
Signal intensity was measured relative to
one of the samples, which was chosen as a ref-
erence to obtain optimal results. To preserve
the optical constraints of common samples, the
spots for the reference sample were acquired
in a linear range of nonsaturated dilutions (11).
The distance between the two fitted lines in
log–log space was calculated from the actual
ratios between the current samples and the 
references. We chose the sample of MDA435
cells treated with 10 µM AEE788 because the
behavior of its nonsaturated spots was supe-
rior with respect to linearity of signal intensity
compared to that of samples treated with the
other primary antibodies.
Signal intensity was normalized to that of
β-actin (positive control) and ranged from
0.944 to 1.062. Because the levels of phospho-
rylated and nonphosphorylated signaling pro-
teins differed in each of the three cell lines, we
used the expression levels for each cell line
and drug dose to calculate a Pearson correla-
tion matrix highlighting relationships among
the various primary antibodies. 
Results
Cell Killing
At the doses used, each drug produced only
modest effects on cell killing. These data are
summarized in Table 1 for the three cell lines.
Of interest is the observation that the effect 
Fig. 1. Intensity of staining with anti-Src(pY418) anti-
body at 1:1, 1:4, 1:8, 1:16, and 1:32 dilutions in
MDA231 cells treated with 0 or 10 µM SIG11293.
Data shown are means ± standard error of triplicate
values. No distance corrections were made. Expo-
nential least squares fitting to all 0 µM data points
(—) was done using the equation Y = 0.956–1.142X with
R2 = 0.88; fitting for 10 µM points (– –) was done
using Y = 0.695–1.156X with R2 = 0.91.
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of SIG11293 on cell killing was greatest in
MDA231 cells and least on MDA435 cells,
whereas for AEE788, it was greatest in MDA435
cells and equal in U251HF and MDA231 cells.
These data imply that the two drugs produce
their effects on cell killing by somewhat dis-
similar means. In no case did we see the type
of cell killing observed with cytotoxic alkylat-
ing agents where dose-dependent log cell kill
is typically observed. 
Reverse Lysate Array
The data obtained for the two drugs were
quite similar with respect to the intensity of
antibody staining. The data for normalization
of the intensities of the primary antibodies 
to that of the control β-actin antibody are
shown in Table 2. There was good internal
agreement among the cell lines and drug
groups. However, there appeared to be differ-
ences among the cell lines in the absolute
levels of Src(pY418), Src(pY529), panSrc,
Stat3(pY705), activated caspase-3, p38MAPK,
and p70S6K proteins. U251HF cells had
lower absolute values than did MDA231 and
MDA435 cells, which appeared to be similar
with respect to these proteins.
After treatment with the two drugs, changes
were observed with respect to the amounts of
specific proteins and phosphoproteins. To com-
pare changes in the proteins with respect to
increasing drug dose, cell line, and drug, the
following formula was used: 
P = (1 – It/Ic) × 100 (1)
in which P is percent change, It is intensity of
drug-treated sample, and Ic is intensity of con-
trol sample (no drug).
Table 3 shows that, exclusive of β-actin, the
seven proteins varied from their control inten-
sities in different ways in response to the
drugs. To simplify viewing, the mean change
in protein is shown with its p-value for the
change based on a t-test for sample means. For
SIG11293, the effect on the three cell lines 
was directionally down for Src(pY529) and
Stat3(pY705). Although it was up in the three
cell lines for p38MAPK, it was most promi-
nent in the U251 cells (p = 0.01). U251 was
also unique in that this cell line was the only
one to increase panSrc and Src(pY418) levels
(neither significant) in response to SIG11293.
AEE788 increased Stat3(pY705) significantly
(p = 0.002) in MDA435 cells but to a lesser
extent in the other cell lines. Activated cas-
pase 3 increased in all lines, p38MAPK in
U251 and MDA435 cells. AEE788 increased
panSrc in U251 and MDA435 cells and
increased Src(pY418) in all cell lines. 
The relationship between these directional
changes in protein levels, the dose of each
drug, and the cell line used were evaluated
using a Pearson correlation matrix (summa-
rized in Table 4). The correlation coefficients
ranged from –1 (inverse relationship) to +1
(direct relationship); 0 indicated the absence of
a linear relationship. The closer the coefficient
approaches +1 or –1 the more significant 
the correlation to direct or inverse movement
Table 1
Cell Killing Induced by SIG11293 and AEE788 
in Three Cell Lines at 24 ha
% Cell kill
Dose µM SIG11293 AEE788
U251HF 0 0 0
0.1 12 6
1 68 3
10 69 33
MDA435 0 0 0
0.1 −8 50
1 25 42
10 50 42
MDA231 0 0 0
0.1 0 0
1 50 21
10 78 33
aCell kill = (1 – treated cell number/control cell
number) × 100.
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of the protein relative to the increase of 
drug dose.
Discussion
Our data show some differences in the
effects of SIG11293, a primary Src-kinase
inhibitor, and AEE788, a primary EGFR/
ErbB-2 kinase inhibitor and secondary Src-
kinase/Abl-kinase inhibitor. We found that
AEE788 was modestly better than SIG11293 at
cell killing and that although the two drugs
shared some features with regard to protein
and phosphoprotein levels, there were major
differences in Stat3(pY705), Src(pY418), and
Src(pY529) levels. As expected, SIG11293 was
selective for Src kinase, had nearly equal activ-
ity against Lck, and had less than 10% of Src
activity against other Src-family kinases,
EGFR, and platelet-derived growth factor
receptor (1). In contrast, AEE788 inhibited Kdr,
EGFR/ErbB-2, Src, c-abl, c-fms, and Flt-1, with
a 30-fold greater effect against EGFR and a 10-
fold greater effect against ErbB2 compared
with Src (2). Because Kdr is not especially
important in the cultured cell lines studied
here, we surmised that other targets, such as
EGFR, Src, c-abl, and c-fms, would be the
more likely functional targets of AEE788 in
our monolayer culture studies. 
The Pearson correlation matrices (Table 4)
indicate that SIG11293 produces two common
effects on all three cell lines: decreased
Stat3(pY705) and Src(pY529). In our analysis,
correlation coefficients greater than 0.95 were
considered significant at p < 0.05; however, we
believe that it is also of value to look at trends
for which the correlation coefficient is  +0.70
or more or –0.70 or less. The added insight
from these observations is that the three cell
lines appeared to differ somewhat in their
responses to increasing doses of SIG11293:
MDA435 cells showed decreased p38MAPK;
U251HF cells showed a unique increase in
activated caspase 3, panSrc, Src(pY418), and
p70S6K; and MDA231 cells showed no addi-
tional changes in protein expression or phos-
phorylation although Src(pY418) appeared to
trend down. For AEE788, the trends in protein
expression and phosphorylation had few sim-
ilarities among the three cell lines. For
MDA435 cells, AEE788 did not have any signif-
icant effect (≥+0.70 or ≤–0.70) on expression or
phosphorylation of any of the proteins; this
may indicate that AEE788 acts more through
Table 2
Normalization of Initial Antibody Intensity to β-Actin for the Two Separate Drug Studiesa
Relative antibody intensity
Src Src Stat3 Activated 
Cell line (pY418) (pY529) panSrc (pY705) caspase 3 p38MAPK p70S6K
U251HF 0.317 0.677 0.195 0.140 0.144 0.290 0.135
0.365 0.671 0.247 0.154 0.140 0.292 0.116
Mean 0.341 0.674 0.221 0.147 0.142 0.291 0.126
MDA435 0.482 0.836 0.364 0.402 0.193 0.582 0.174
0.480 0.827 0.358 0.433 0.192 0.562 0.166
Mean 0.481 0.832 0.361 0.418 0.193 0.572 0.170
MDA231 0.467 0.755 0.373 0.403 0.200 0.475 0.163
0.424 0.749 0.353 0.376 0.194 0.517 0.171
Mean 0.446 0.752 0.363 0.390 0.197 0.496 0.167
aThe cell lines are nominally ordered by increasing intensity.
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the Ras and MAPK pathways because it
inhibits EGFR/ErbB-2. For U251HF cells,
there was a decrease in Src(pY529) and
increase in activated caspase-3. In MDA231
cells, there was a decrease in Src(pY529) and
Stat3(pY705). Although the Pearson correla-
tion coefficients were not always less than
–0.70, activated caspase-3 appears to have
increased in all cell lines in response to
AEE788, but only in U251HF cells in response
to SIG11293. Thus, the data in Tables 1, 3,
and 5 suggest that the signaling mechanisms
responsible for the cell killing induced by
AEE788 is related to caspase-3-mediated
apoptosis and only for U251HF in the case of
SIG11293.
Because both drugs inhibit Src kinase, we
compared the effects of the highest dose 
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Table 4
The Pearson Correlation Matrix for the Effect of SIG11293 or AEE788 on Each Cell Linea
SIG11293 AEE788
U251HF (69%) Coefficient U251HF (33%) Coefficient
Dose 1 Dose 1
p70S6K 0.91 Cell kill 0.98
Src (pY418) 0.89 Activated caspase 3 0.72
panSrc 0.84 panSrc 0.60
Activated caspase 3 0.71 p70S6K 0.52
Cell kill 0.65 p38MAPK 0.23
p38MAPK 0.61 Src (pY418) 0.16
Src (pY529) –0.75 Stat3 (pY705) –0.68
Stat3 (pY705) –0.98 Src (pY529) –0.92
MD435 (50%) Coefficient MD435 (42%) Coefficient
Dose 1 Dose 1
Cell kill 0.89 Activated caspase 3 0.67
Activated caspase 3 0.14 p70S6K 0.64
p70S6K –0.09 Stat3 (pY705) 0.43
panSrc –0.45 panSrc 0.36
Src (pY418) –0.61 Cell kill 0.29
p38MAPK –0.78 Src (pY418) –0.06
Src (pY529) –0.90 p38MAPK –0.08
Stat3 (0pY705) –0.95 Src (pY529) –0.49
MDA231 (78%) Coefficient MDA231 (33%) Coefficient
Dose 1 Dose 1
Cell kill 0.85 Cell kill 0.85
Activated caspase 3 0.06 Activated caspase 3 0.68
p70S6K –0.25 p70S6K 0.66
panSrc –0.44 panSrc 0.07
p38MAPK –0.54 Src (pY418) –0.20
Src (pY418) –0.64 p38MAPK –0.24
Src (pY529) –0.91 Stat3 (pY705) –0.74
Stat3 (pY705) –0.95 Src (pY529) –0.90
aValues in parentheses are the cell kill 24 h after 10 µM of drug exposure.
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(10 µM) of each drug on Src (Table 5). Under
those conditions, there appears to be some
commonality in the direct effects of the two
drugs on Src kinase. When looking at Src
autophosphorylation, if the amounts of
Src(pY418) and Src(pY529) were normalized to
that of panSrc, then Src(pY529), the negative
regulatory site of activated Src, was decreased
by both drugs to a greater extent than was
Src(pY418), the positive regulatory site of acti-
vated Src. Thus, it can be appreciated that one
would have a false impression of the impact
of both drugs on Src(pY418) if only β-actin
normalization was used and no consideration
was given to the rising Src protein (panSrc)
level in the one cell line. From a mechanistic
point of view, these Src-phosphoprotein obser-
vations will require further study with other
Src-kinase inhibitors. 
The biological effects of the two drugs on the
three cell lines are still not fully understood.
Our observations pertain only to cells in culture,
so we do not know whether the perturbations
in signal transduction would be the same in a
tumor in situ. Unfortunately, it is much more
difficult today to study drugs’ effects on solid
tumors using reverse lysate arrays because of
the amount of protein required for the cur-
rent generation of detection instruments. We
believe, however, that our findings show the
benefit of reverse lysate arrays in studying
the quantitative effects of drugs on signaling
pathways. We are expanding these studies to
examine a wider variety of proteins in cul-
tured cells, and we are developing techniques
for replicating our studies in xenografts of
the same three tumor cell lines. It is hoped
that the added insights from these expanded
experiments will aid in the design of better
chemotherapies for cancer patients.
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